Feature | March 18, 2014

Mevion S250 Proton Accelerator Delivered to First Coast Oncology in Florida

Proton Therapy Radiation Therapy Mevion S250

March 18, 2014 — Mevion Medical Systems delivered its Mevion S250 proton therapy superconducting synchrocyclotron accelerator to the physician-owned proton therapy center at First Coast Oncology in Jacksonville, Fla.

The Mevion S250 proton therapy system is a single-room, gantry-mounted proton accelerator. It is meant to free hospitals and private treatment facilities from the costs, prohibitive space requirements and cumbersome processes that to date have defined this effective treatment modality. 

After a four-day journey from Mevion’s headquarters outside Boston, the accelerator was delivered and mounted onto its rotating gantry. Mevion’s installation team will complete the installation and move into acceptance testing and commission of the system this year.

The Mevion S250 is also installed at the Kling Proton Therapy Center at Barnes-Jewish Hospital at Washington University in St. Louis, Mo. Four additional MEVION S250 proton therapy systems are under installation at Robert Wood Johnson University Hospital in New Brunswick, N.J.; Stephenson Cancer Center at the University of Oklahoma in Oklahoma City, Okla.; University of Florida Health Cancer Center at Orlando Health; and University Hospitals Seidman Cancer Center in Cleveland, Ohio.

For more information: www.mevion.com 

Related Content

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation Therapy, MRI guided RT.
Sponsored Content | Webinar | Radiation Therapy | October 13, 2017
The webinar "Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation" will be presented by Par
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Overlay Init